Abbott has signed an agreement to acquire all global rights to develop and commercialize AP214 from Action Pharma. AP214 is a hormone analogue which is being developed to prevent acute kidney injury associated with major cardiac surgery ...
Tags: AP214, Abbott, Action Pharma